跳至主要内容
临床试验/NL-OMON56933
NL-OMON56933尚未招募3 期

Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-risk rectal cancer. - REACT

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 206 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
206

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age >= 18 years
  • WHO performance score 0-1
  • Informed consent for PLCRC with specific consent for additional blood
  • withdrawals and offering of future experimental research
  • Histological confirmed rectal cancer; either treated with neoadjuvant
  • (chemo)radiotherapy, and/or clinical T4 and/or N+ in case no neoadjuvant
  • therapy was administered.
  • Eligible to receive treatment with combination adjuvant chemotherapy
  • (CAPOX/FOLFOX) according to the treating physician

排除标准

  • Another malignancy in previous 5 years, with the exception of treated
  • carcinoma in situ or skin cancer other than melanoma
  • Incomplete primary tumour resection (R1 or R2 resection)
  • Contra-indication for fluoropyrimidines or oxaliplatin
  • Neoadjuvant oxaliplatin based systemic treatment, e.g. treated with the
  • RAPIDO regimen consisting of short course radiotherapy followed by 6 cycles of
  • CAPOX or 9 cycles of FOLFOX prior to surgery
  • Patients with a clinical complete response, who will not undergo surgery.
  • Pregnant and lactating women

研究者

相似试验